ClinicalTrials.gg
Not yet recruitingNCT06091605Updated Nov 17, 2026

Evaluation of Omega Roll Envelope Flap for Soft Tissue Augmentation Around Osseointegrated Dental Implants

An interventional study of Soft tissue augmentation around dental implants. in Soft Tissue Augmentation and Dental Implants, sponsored by Ain Shams University. Not yet recruiting. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 17, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Abstract Statement of the problem: Peri-implant soft-tissue augmentation procedures can be broadly divided into two groups, depending on their primary therapeutic objective: (1) Peri-implant soft-tissue phenotype modification and (2) Treatment of peri-implant marginal mucosa defects (PMMDs), also known as peri-implant soft-tissue dehiscences.

Aim of the study: The aim of this study will be to evaluate the efficacy of the Omega roll envelope flap (OREF) technique compared to the conventional envelope split-thickness flap technique combined with an autogenous connective tissue graft, in enhancing Peri-implant soft tissue phenotype defined by the gingival thickness, keratinized tissue width, mucosal margin level and interproximal papilla height around implant.

Read the detailed description

Materials and Methods: 24 patients complaining of a single missing tooth in the with adjacent intact natural teeth and demanding replacing it with the best possible esthetics will be enrolled and recruited from the outpatient clinic, Faculty of Dentistry, Ain Shams University according to eligibility criteria. They will be randomly allocated to two equal groups. Group A (test group, n=12) will have a single implant placed after receiving non-surgical periodontal therapy and then after 12 weeks at the uncovering of the implant and placement of healing abutment, an Omega roll envelope flap (OREF) technique will be carried out for soft tissue augmentation, while Group B (control group, n=12) same procedures will be done but, soft tissue augmentation will be done by an envelope split-thickness flap combined with a sub-epithelial connective tissue graft. After 3 and 6 months Peri-implant soft tissue phenotype defined by gingival thickness, keratinized tissue width, mucosal margin level and interproximal papilla height around implant will be clinically assessed (1ry outcome). The 2ry outcomes will include comparing between the probing depth and clinical attachment level. Postoperative pain and swelling will be recorded by the patient for the 1st two weeks post-surgically. Postoperative instructions and medication will be given to the patient. All readings will be carried out by a calibrated outcome assessor who will be blinded. Data collected will be tabulated and statistically analyzed.

02

Conditions studied

  • Soft Tissue Augmentation
  • Dental Implants
03

In context

Lead sponsor

Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Systemically free patients ( (ASA) I. Patients between 18 - 50 years of both genders and able to understand the nature of the proposed surgery and to sign the . Ability to comply with the study related procedures such as maintaining good oral hygiene and attending all follow-up scheduled appointments. Patients who complained of a single missing tooth bounded with two adjacent natural sound teeth diagnosed with clinical periodontal health. Necessity for soft tissue augmentation in a single tooth gap determined by a concavity that was present in the edentulous area or tissues with thin biotype being ≤2 mm or with inadequate width of ≤4mm. Adequate bone width for implant placement without need for bone augmentation (confirmed by a single pre-operative cone-beam computed tomography) (CBCT).

Exclusion criteria

Exclusion Criteria:

  • Previous soft tissue augmentation in the area. Need for major soft or hard tissue augmentation procedures. Smokers. Patients taking medications that might affect the healing of soft and hard peri-implant tissues.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Omega roll envelope flap (OREF) technique

    Patients will undergo peri-implant soft tissue augmentation procedures accompanied by the placement of healing abutments at the uncovering of the inserted osseo-integrated implants, 12 weeks after the initial stage of implant placement. Omega roll envelope flap (OREF) technique will be done around the placed healing abutment, then suturing will be done.

    Procedure: Soft tissue augmentation around dental implants.

  • Active comparator
    Envelope flap combined with a sub-epithelial connective tissue graft

    Patients will undergo peri-implant soft tissue augmentation procedures accompanied by the placement of healing abutments at the uncovering of the inserted osseo-integrated implants, 12 weeks after the initial stage of implant placement. An envelope split thickness flap will be made at the concerned implant site and a connective tissue graft will be harvested from the tuberosity and then adapted to the placed healing abutment at the surgical site and suturing will be done.

    Procedure: Soft tissue augmentation around dental implants.

Interventions

  • ProcedureSoft tissue augmentation around dental implants.

    Soft tissue augmentation around dental implants using Omega roll envelope flap (OREF) technique.

    Also known as: Soft tissue augmentation around dental implants using Envelope flap combined with a sub-epithelial connective tissue graft.

06

What researchers measure

Primary outcomes

  1. Peri-implant soft tissue phenotype

    Measured in millimeters, using UNC-15 Periodontal Probe/Endodontic File with rubber stopper,

    Time frame: Baseline, 3 Months & 6 Months

Secondary outcomes

  1. Postoperative pain

    Numerical rating scale (Visual analog scale) Scores (0-10)

    Time frame: At the day of the procedure and for 14 days (registered before bedtime at a specific time point for each patient)

  2. Postoperative swelling

    Numerical rating scale (Visual analog scale) Scores (0-10)

    Time frame: At the day of procedure and for 7 days (registered before bedtime at specific time point for each patient)

  3. Implant soft tissue deficiency Esthetic Score (IDES)

    Scores of: * Soft Tissue Margin (STM) (0-5): 0= No improvement of the PSTD and 5=Complete coverage of the metallic components with the mucosal margin at the same level of the homologous tooth. * Peri-implant papillae height (PPH) (0-3): 0=Both papillae are more apical than the healthiest papilla tip of the homologous tooth and 3=Both papillae are at the same level (or more coronal) of the healthiest papilla tip of the homologous tooth. * Peri-implant Mucosa (PMC) (0-1): 0=Distinguishable from the adjacent soft tissue and 1=Not distinguishable from the adjacent soft tissue. * Peri-implant Mucosa Appearance (PMA) (0-1): 0=Presence of at least one of these conditions: scar tissue, MGJ not-aligned, tissue volume too thin or too thick compared to the adjacent soft tissue or tissue texture not similar to the adjacent soft tissue and 1=Absence of scar tissue, MGJ well aligned, tissue volume in line with the adjacent soft tissue or tissue texture similar to the adjacent soft tissue.

    Time frame: At 6 months

  4. Esthetic satisfaction

    Numerical rating scale (Visual analog scale) Scores (0-10)

    Time frame: At 3 and 6 months

  5. Probing depth

    Using UNC-15 Periodontal Probe

    Time frame: Baseline, 3 Months & 6 Months

  6. Clinical Attachment Level (CAL)

    Using UNC-15 Periodontal Probe 0mm= Normal \<1-2mm= Stage 1 Periodontitis \<3-4mm= Stage 2 Periodontitis \>5mm= Stage 3 and 4 Perodontitis

    Time frame: Baseline, 3 Months & 6 Months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for May 2027, 6 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: start Nov 2023 → Nov 2026, primary completion Nov 2024 → May 2027 and completion May 2025 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2023
First posted
Oct 19, 2023
StartEst.
Nov 1, 2026was Nov 2023
Primary completionEst.
May 1, 2027was Nov 2024
CompletionEst.
Aug 1, 2027was May 2025
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Nov 1, 2023→Nov 1, 2026
Nov 17, 2026
Primary completion
Nov 1, 2024→May 1, 2027
Nov 17, 2026
Study completion
May 1, 2025→Aug 1, 2027
Nov 17, 2026
Design
Phase 4→Not applicable
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Start date Nov 1, 2023→Nov 1, 2026
    Primary completion Nov 1, 2024→May 1, 2027
    Study completion May 1, 2025→Aug 1, 2027
    Design Phase 4→Not applicable
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06091605
Responsible party
Amr Mohamed Saeed Abd El Aziz (Phd Researcher, Ain Shams University) — Principal investigator
First posted
Oct 19, 2023
Start date
Nov 1, 2026 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Amr M Saeed, Msc of Perio.
Contact
amrsaeed92@gmail.com
01111304015 ext. 002-
Mohamed S Abd El Aziz
Contact
01002209759 ext. 002-

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion